Ovarian cancer, from the laboratory to the clinic: Challenges for the future-Reference-Cited by-同舟云学术

Ovarian cancer, from the laboratory to the clinic: Challenges for the future

Published:1996-01 Issue:1 Volume:7 Page:9-13
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Kaye S.B.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/7/1/9/439275/7-1-9.pdf

Reference26 articles.

1. The epidemiology of ovarian cancer;Beral,1987

2. Medical audit, cancer registration, and survival in ovarian cancer;Gillis;Lancet,1991

3. Characterization of a cisplatin-resistant human ovarian cancer cell line and its use in the evaluation of platinum analogues;Behrens;Cancer Res,1987

4. Cellular pharmacology of cisplatin: Perspectives on mechanisms of required resistance;Andrews;Cancer Cells,1990

5. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine;O'Dwyer;J Natl Cancer Inst,1992

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A risk stratification and prognostic prediction model for lung adenocarcinoma based on aging-related lncRNA;Scientific Reports;2023-01-10

2. Genetic Epidemiology of Mismatch Repair Deficiency in Ovarian Cancer;Environmental Factors, Genes, and the Development of Human Cancers;2010

3. A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer;Cancer;2008-08-15

4. Intraperitoneal chemotherapy for ovarian cancer;Current Oncology Reports;2003-11

5. Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene–Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian Cancer;Journal of Clinical Oncology;2002-03-15